Regulation and therapy: the role of ferroptosis in DLBCL

Yifan Wang; Yifan Wang; Zhengmei He; Zhengmei He; Xinyu Dong; Xinyu Dong; Yiming Yao; Yiming Yao; Qiuni Chen; Qiuni Chen; Yuye Shi; Yuye Shi; Yuan Deng; Yuan Deng; Quane Zhang; Quane Zhang; Liang Yu; Liang Yu; Liang Yu; Chunling Wang; Chunling Wang; Chunling Wang

doi:10.3389/fphar.2024.1458412

Frontiers in Pharmacology (Jan 2025)

Regulation and therapy: the role of ferroptosis in DLBCL

Yifan Wang,
Yifan Wang,
Zhengmei He,
Zhengmei He,
Xinyu Dong,
Xinyu Dong,
Yiming Yao,
Yiming Yao,
Qiuni Chen,
Qiuni Chen,
Yuye Shi,
Yuye Shi,
Yuan Deng,
Yuan Deng,
Quane Zhang,
Quane Zhang,
Liang Yu,
Liang Yu,
Liang Yu,
Chunling Wang,
Chunling Wang,
Chunling Wang

Affiliations

Yifan Wang: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Yifan Wang: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Zhengmei He: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Zhengmei He: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Xinyu Dong: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Xinyu Dong: Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, China
Yiming Yao: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Yiming Yao: Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, China
Qiuni Chen: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Qiuni Chen: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Yuye Shi: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Yuye Shi: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Yuan Deng: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Yuan Deng: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Quane Zhang: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Quane Zhang: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Liang Yu: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Liang Yu: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Liang Yu: Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, China
Chunling Wang: Department of Hematology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China
Chunling Wang: Northern Jiangsu Institute of Clinical Medicine, Nanjing Medical University, Nanjing, China
Chunling Wang: Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai’an, China

DOI: https://doi.org/10.3389/fphar.2024.1458412
Journal volume & issue: Vol. 15

Abstract

Read online

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin’s lymphoma (NHL), up to 30%–40% of patients will relapse and 10%–15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode discovered in recent years. Its occurrence pathway plays an essential impact on the therapeutic effect of tumors. Numerous studies have shown that modulating critical factors in the ferroptosis pathway can influence the growth of tumor cells in hematological malignancies including DLBCL. This review highlights recent advances in ferroptosis-related genes (FRGs), including STAT3, Nrf2, and ZEB1, and focuses on the clinical potential of ferroptosis inducers such as IKE, α-KG, DMF, and APR-246, which are currently being explored in clinical studies for their therapeutic effects in DLBCL. Correlational studies provide a novel idea for the research and treatment of ferroptosis in DLBCL and other hematological malignancies and lay a solid foundation for future studies.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords